Curious about McKesson (MCK) Q1 Performance? Explore Wall Street Estimates for Key Metrics

McKesson’s (MCK) upcoming quarterly report is expected to show earnings of $9.44 per share, up 14.3% from the year-ago period. Analysts forecast revenue of $104.39 billion, representing year-over-year growth of 6.7%. The consensus EPS estimate has risen 0.2% over the past 30 days, reflecting analysts’ reassessment of their initial projections. Estimate revisions can provide an important signal of changing expectations and may influence short-term investor behavior. Historical analysis has also found a strong relationship between earnings-estimate revision trends and short-term share-price performance. Beyond headline earnings and revenue, McKesson’s segment forecasts provide a more detailed view of expected results. Revenue from North American Pharmaceutical is projected at $86.53 billion, down 3.8% from the prior-year quarter. Prescription Technology Solutions revenue is expected to reach $1.50 billion, up 4.5% year over year. Medical-Surgical Solutions revenue is forecast at $2.79 billion, representing 3.3% growth. Analysts expect adjusted operating profit from North American Pharmaceutical to total $806.45 million, compared with $950.00 million in the same quarter last year. Adjusted operating profit for Medical-Surgical Solutions is projected at $241.06 million, versus $244.00 million a year earlier. Prescription Technology Solutions is expected to generate adjusted operating profit of $302.62 million, compared with $269.00 million in the year-ago quarter. The estimates point to contrasting segment trends: growth in Prescription Technology Solutions and relative stability in Medical-Surgical Solutions could partly offset weaker North American Pharmaceutical revenue and profitability. Investors will assess whether reported results meet the $9.44 EPS and $104.39 billion revenue forecasts and whether management’s figures confirm these operating trends. McKesson shares have gained 10.1% over the past month, outperforming the 0.5% decline in the Zacks S&P 500 composite. With a Zacks Rank #2 (Buy), MCK is expected to outperform the broader market in the near term.